Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT

Synapse

Volumn 59, Issue 6, 2006, Pages 330-341

  Jagoda, Elaine M ^a   Lang, Lixin ^a   Tokugawa, Joji ^a   Simmons, Ashlie ^a   Ma, Ying ^a   Contoreggi, Carlo ^b   Kiesewetter, Dale ^a   Eckelman, William C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

5 HT; 5 HT1A receptors; FPWAY; PET

Indexed keywords

FENFLURAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; SEROTONIN; SEROTONIN 1A RECEPTOR; URETHAN; CYCLOHEXANE DERIVATIVE; FLUORINE; LIGAND; N (2 (4 (2 METHOXYPHENYL)PIPERAZINO)) N (2 PYRIDINYL) TRANS 4 FLUOROCYCLOHEXANECARBOXAMIDE; N-(2-(4-(2-METHOXYPHENYL)PIPERAZINO))-N-(2-PYRIDINYL) TRANS-4-FLUOROCYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN BLOOD FLOW; CEREBELLUM; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG UPTAKE; EX VIVO STUDY; HETEROZYGOTE; HIPPOCAMPUS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; BRAIN LEVEL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; DRUG INTERACTION; METABOLISM; METHODOLOGY; MOUSE MUTANT; PHYSIOLOGY; RADIOASSAY; SPRAGUE DAWLEY RAT; TIME; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; BRAIN; BRAIN CHEMISTRY; CYCLOHEXANES; DRUG INTERACTIONS; FLUORINE RADIOISOTOPES; LIGANDS; MALE; MICE; MICE, KNOCKOUT; PIPERAZINES; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN ANTAGONISTS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 33645422467     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20246     Document Type: Article

References (42)

1. Carson RE, Lang L, Watabe H, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC. 2000. PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. Nucl Med Biol 27:493-497.
2. Carson RE, Lang L, Watabe H, Ma Y, Der MG, Herscovitch P, Eckelman WC. 2001. PET evaluation of two F-18-labeled 5-HT1A antagonists with intermediate affinity. J Nucl Med 42(Suppl 5):395.
3. De Groote L, Olivier B, Westenberg HG. 2002. The effects of selective serotonin reuptake inhibitors on extracellular 5-HT levels in the hippocampus of 5-HT(1B) receptor knockout mice. Eur J Pharmacol 439:93-100.
4. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. 2004. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 10:1493-1503.
5. Faber JE, Harris PD, Wiegman DL. 1993. Anesthetic depression of microcirculation, central hemodynamics, and respiration in decerebrate rats. Am J Physiol 243:H837-H843.
6. Fletcher A, Cliffe IA, Dourish CT. 1993. Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol Sci 14:41-48.
7. Fracasso C, Guiso G, Confalonieri S, Bergami A, Garattini S, Caccia S. 1995. Depletion and time-course of recovery of brain serotonin after repeated subcutaneous dexfenfluramine in the mouse. A comparison with the rat. Neuropharmacology 34:1653-1659.
8. Gardier AM, Malagie I, Trillat AC, Jacquot C, Artigas F. 1996. Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 10:16-27.
9. Giovacchini G, Lang L, Ma Y, Herscovitch P, Eckelman WC, Carson RE. 2004. Differential effects of the selective serotonin re-uptake inhibitor paroxetine on raphe and cortical 5-HT1A binding; A PET study in monkey with [18F]FPWAY Neuroimage 22(Suppl 2):T25-T26.
10. Gobbi G, Murphy DL, Lesch K, Blier P. 2001. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J Pharmacol Exp Ther 296:987-995.
11. Guan XM, Peroutka SJ, Kobilka BK. 1992. Identification of a single amino acid residue responsible for the binding of a class of β-adrenergic receptor antagonists to 5-hydroxytryptamine 1A receptors. Mol Pharmacol 41:695-698.
12. He M, Sibille E, Benjamin D, Toth M, Shippenberg T. 2001. Differential effects of 5-HT1A receptor deletion upon basal and fluoxetine-evoked 5-HT concentrations as revealed by in vivo microdialysis. Brain Res 902:11-17.
13. Hoyer D, Pazos A, Probst A, Palacios JM. 1986. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res 376:85-96.
14. Hume S, Hirani E, Opacka-Juffry J, Myers R, Townsend C, Pike V, Grasby P. 2001. Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(1A) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine. Synapse 41:150-159.
15. Lang L, Jagoda E, Schmall B, Vuong BK, Adams HR, Nelson DL, Carson RE, Eckelman WC. 1999. Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem 42:1576-1586.
16. Lang L, Jagoda E, Schmall B, Sassaman M, Ma Y, Eckelman WC. 2000a. Fluoro analogs of WAY-100635 with varying pharmacokinetics properties. Nucl Med Biol 27:457-462.
17. Lang L, Ma Y, Jagoda E, Eckelman WC. 2000b. 18F labeled 4-cis and -trans FCWAY and 3-cis and -trans FCWAY. J Nucl Med 41:39P.
18. Le Bars D, Lemaire C, Ginovart N, Plenevaux A, Aerts J, Brihaye C, Hassoun W, Leviel V, Mekhsian P, Weissmann D, Pujol JF, Luxen A, Comar D. 1998. High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. Nucl Med Biol 25:343-350.
19. Maeda J, Suhara T, Ogawa M, Okauchi T, Kawabe K, Zhang MR, Semba J, Suzuki K. 2001. In vivo binding properties of [carbonyl-11C]WAY-100635: effect of endogenous serotonin. Synapse 40:122-129.
20. Maggi CA, Meli A. 1986a. Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 1: General considerations. Experientia 42:109-114.
21. Maggi CA, Meli A. 1986b. Suitability of urethane anesthesia for physiopharmacological investigations. Part 3: Other systems and conclusions. Experientia 42:531-537.
22. 1A receptors with positron emission tomography. Life Sci 55:PL403-PL407.
23. McCann U, Hatzidimitriou G, Ridenour A, Fischer C, Yuan J, Katz J, Ricaurte G. 1994. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther 269:792-798.
24. Meneses A. 1999. 5-HT system and cognition. Neurosci Biobehav Rev 23:1111-1125.
25. Pardridge WM. 1997. Drug delivery to the brain. J Cereb Blood Flow Metab 17:713-731.
26. Passchier J, van Waarde A, Doze P, Elsinga PH, Vaalburg W. 2000. Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats. Eur J Pharmacol 407:273-280.
27. Rice OV, Gatley SJ, Shen J, Huemmer CL, Rogoz R, DeJesus OT, Volkow ND, Gifford AN. 2001. Effects of endogenous neurotransmitters on the in vivo binding of dopamine and 5-HT radiotracers in mice. Neuropsychopharmacology 25:679-689.
28. Rocher C, Gardier AM. 2001. Effects of repeated systemic administration of d-fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis. Naunyn Schmiedebergs Arch Pharmacol 363:422-428.
29. Roda F, Pio J, Bianchi AL, Gestreau C. 2004. Effects of anesthetics on hypoglossal nerve discharge and c-Fos expression in brainstem hypoglossal premotor neurons. J Comp Neurol 468:571-586.
30. Rothman RB, Baumann MH. 2002. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects. Pharmacol Biochem Behav 71:825-836.
31. Rowland NE, Carlton J. 1986. Neurobiology of an anorectic drug: fenfluramine. Prog Neurobiol 27:13-62.
32. Saxena PR. 1995. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther 66:339-368.
33. Severs WB, Keil LC, Klase PA, Deen KC. 1981. Urethane anesthesia in rats. Altered ability to regulate hydration. Pharmacology 22:209-226.
34. Seyde WC, McGowan L, Lund N, Duling B, Longnecker DE. 1985. Effects of anesthetics on regional hemodynamics in normovolemic and hemorrhaged rats. Am J Physiol 249(1 Part 2):H164-H173.
35. Sharif NA, Drace CD, Williams GW, Crider JY. 2004. Cloned human 5-HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation. J Pharm Pharmacol 56:1267-1274.
36. Sharma HS, Olsson Y, Dey PK. 1990. Changes in blood-brain barrier and cerebral blood flow following elevation of circulating serotonin level in anesthetized rats. Brain Res 517:215-223.
37. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N, Nakanishi S. 1999. Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 849:85-96.
38. Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF. 2002. Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys. Synapse 45:207-212.
39. van Wijngaarden I, Tulp MT, Soudijn W. 1990. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 188:301-312.
40. Zhuang ZP, Kung MP, Kung HF. 1994. Synthesis and evaluation of 4-(2′-methoxyphenyl)-1-[2′-[N-(2″-pyridinyl)-p- iodobenzamido]ethyl] piperazine (p-MPPI): a new iodinated 5-HT1A ligand. J Med Chem. 37(10):1406-1407
41. Zhuang X, Gross C, Santarelli L, Compan V, Trillat AC, Hen R. 1999. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 21(Suppl 2):52S-60S.
42. Zimmer L, Mauger G, Le Bars D, Bonmarchand G, Luxen A, Pujol JF. 2002. Effect of endogenous serotonin on the binding of the 5-HT1A PET ligand 18F-MPPF in the rat hippocampus: kinetic β measurements combined with microdialysis. J Neurochem 80:278-286.